---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-23-000024"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:47:40.860705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q1 revenue $14.5M (+27% YoY) and raises FY2023 guidance to $52-54M

## Summary
- Q1 revenue $14.5M, up 27% YoY and 13% sequentially; net loss narrowed to $10.4M from $11.5M.
- Full-year 2023 revenue guidance raised to $52-54M (prior $50-52M), implying 14-19% YoY growth.
- Gross margin 72% vs 73% YoY; operating expenses $18.7M; cash and investments $67.6M.
- RNS System utilization and DIXI Medical distribution drove growth; replacement implants declined.
- NAUTILUS pivotal study for primary generalized epilepsy enrolling as expected.

## SEC filing metadata
- accession: 0001528287-23-000024
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/npce-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-23-000024
- JSON: https://secwatch.observer/filing/0001528287-23-000024.json
- Plain text: https://secwatch.observer/filing/0001528287-23-000024.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported full year 2023 results: revenue $52 million to $54 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $52 million to $54 million
  - Guidance: raised
  - Result: guidance update
  source text: Full Year 2023 Financial Guidance • Increased total revenue guidance to $52 million to $54 million, representing growth of 14% to 19% over 2022, as compared to previously-communicated guidance of $50 million to $52 million • Reiterated gross margin to range between 69% and 71% • Reiterated total operating expenses to range between $75 million and $77 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm
- Earnings Releases
  NeuroPace Inc reported first quarter ended March 31, 2023 results: revenue $14.5 million, net income $10.4 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $14.5 million
  - Net income: $10.4 million
  - Result: reported results
  source text: Total revenue was $14.5 million in the first quarter of 2023, representing growth of 27% compared to the prior year period and 13% compared to the prior quarter. Replacement implant revenue declined compared to the prior year period and represented less than 10% of total revenue in the first quarter of 2023. The decrease in replacement implant revenue was expected as previously implanted patients finish transitioning to the second generation RNS System with a nearly 11-year average battery life. Gross margin for the first quarter of 2023 was 72% compared to 73% in the first quarter of 2022 and 69% in the fourth quarter of 2022. The decline in gross margin compared to the first quarter of 2022 was primarily due to the change in product mix as a result of initiating distribution of DIXI Medical products in the fourth quarter of 2022. Total operating expenses in the first quarter of 2023 were $18.7 million, compared to $18.0 million in the prior year period. R&D expense in the first quart
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828723000024/0001528287-23-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.